Scientific deep-dive

Wegovy for MASH, MAFLD & Fatty Liver: FDA Approval & ESSENCE Evidence Review

In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg weekly) for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis based on the ESSENCE phase 3 trial. ESSENCE results, MASH/MASLD terminology, eligibility, Zepbound status, and AASLD lifestyle adjuncts.

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed
15 min read·9 citations

This MASH evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature. All clinical claims are anchored to a primary source.

In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg weekly) for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. It is the first GLP-1 receptor agonist to carry an FDA-approved liver indication, and the first drug in any class to carry simultaneous FDA-approved indications for chronic weight management, cardiovascular event reduction, and MASH. This article walks through the ESSENCE pivotal trial behind that approval, what MASH/MASLD actually mean under the updated 2023 nomenclature, eligibility for the new indication, the cardiovascular bonus, where Zepbound stands, and the lifestyle adjuncts that AASLD still considers foundational.

The honest answer

Yes — the FDA approved Wegovy for MASH (Metabolic dysfunction-Associated Steatohepatitis, formerly NASH) in August 2025 based on the ESSENCE trial. The approval covers adults with non-cirrhotic MASH and moderate-to-advanced fibrosis. Wegovy improves liver histology AND reduces cardiovascular events (SELECT) — the first GLP-1 with both indications. Zepbound has not received MASH approval yet (SYNERGY-NASH data pending FDA review).

Wegovy’s MASH indication — what FDA approved in August 2025

The supplemental New Drug Application that Novo Nordisk filed for Wegovy in MASH was approved by the FDA in August 2025, and the new indication is now reflected in §1 of the Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, version 18, effective 2026-05-05). The indication language reads, in summary form, that Wegovy is indicated for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis (stage F2 or F3 on the NASH-CRN fibrosis scale).[9]

Three things are notable about how the indication is written. First, the FDA explicitly excludes patients with cirrhosis (fibrosis stage F4) — ESSENCE did not enroll cirrhotic patients and the agency did not extrapolate efficacy beyond the trial population. Second, the dosing is the same as for the chronic- weight-management indication: titration through 0.25, 0.5, 1.0, and 1.7 mg to a maintenance dose of 2.4 mg once weekly. There is no separate “MASH dose” of semaglutide. Third, this is now the third indication on the Wegovy label: chronic weight management (June 2021), cardiovascular risk reduction in adults with established CV disease and obesity (added March 2024 based on SELECT[5]), and MASH (August 2025 based on ESSENCE[1]).

For context on Wegovy’s baseline pharmacology and how it differs from Ozempic at the molecule level — same semaglutide, different maximum dose — see the Wegovy vs Ozempic evidence review. The current article focuses specifically on the MASH expansion.

What MASH/MAFLD actually means (terminology updated in 2023)

The disease names changed in 2023, which is a frequent source of confusion for patients and prescribers who learned the older terminology. The chemistry of the disease did not change; only the name did.

In June 2023 a multisociety Delphi consensus statement (Rinella et al., Hepatology 2023) replaced the previous nomenclature with a new framework anchored on the presence of cardiometabolic risk factors:[7]

Old name (pre-2023)New name (2023+)What it describes
NAFL / NAFLDMASLDLiver fat (hepatic steatosis) in ≥5% of hepatocytes plus at least one cardiometabolic risk factor (BMI, waist circumference, glucose, blood pressure, triglycerides, HDL), without significant alcohol intake or other secondary cause. Broad umbrella diagnosis.
NASHMASHMASLD plus hepatocyte injury (ballooning) and inflammation on biopsy. The more aggressive subset that can progress to fibrosis and cirrhosis. This is the indication Wegovy now carries.
MAFLD (interim)Not the consensus nameA 2020-era term proposed in parallel but not adopted by the AASLD/EASL/ALEH multisociety consensus. The 2023 Delphi statement settled on MASLD/MASH; MAFLD persists in some regional usage but is not the FDA or AASLD term.

The 2024 AASLD update (Kanwal et al., Hepatology 2024) mapped the prior NAFLD practice guidance onto the new MASLD/MASH nomenclature without changing clinical recommendations substantively.[8] The bottom line for patients: if your prior records say “NASH,” that is the same disease your new records will call “MASH.”

Within MASH, the FDA approval and the ESSENCE trial both stratify patients by fibrosis stage, which is measured on the NASH-CRN scale of F0 through F4: F0 is no fibrosis, F1 is mild fibrosis, F2 is moderate fibrosis with bridging beginning, F3 is advanced bridging fibrosis, and F4 is cirrhosis. The Wegovy MASH indication covers F2 and F3 specifically. Patients with F0-F1 MASH and patients with F4 (cirrhosis) are not in the labeled population.

ESSENCE trial: design, endpoints, results

ESSENCE (Sanyal et al., NEJM 2025) is the phase 3 pivotal trial behind the Wegovy MASH approval. It randomized 1,197 adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis (NASH- CRN stage F2 or F3) to once-weekly semaglutide 2.4 mg or placebo, on a background of lifestyle counseling. Both arms followed the standard Wegovy titration ladder. Liver biopsies were obtained at baseline and again at week 72 and read centrally by blinded pathologists.[1]

The trial had two co-primary histologic endpoints, both of which had to be hit for the indication to be approved:

  • Resolution of steatohepatitis without worsening of fibrosis at week 72. Result: 62.9% on semaglutide vs 34.3% on placebo. A difference of approximately 28.6 percentage points in favor of semaglutide.
  • Improvement of fibrosis by at least one stage without worsening of MASH at week 72. Result: 36.8% on semaglutide vs 22.4% on placebo. A difference of approximately 14.4 percentage points in favor of semaglutide.

Both co-primary endpoints achieved statistical significance, which is the standard the FDA had set when it issued draft MASH-trial guidance to industry in 2018. ESSENCE was the first GLP-1 to meet both endpoints in a phase 3 design.

Secondary endpoints reinforced the histologic picture. Mean body- weight reduction in the semaglutide arm was approximately −10.5% vs −2.0% on placebo. Liver enzymes (ALT, AST) declined meaningfully in the semaglutide arm. Non-invasive markers of liver fat (MRI-PDFF in a substudy) and fibrosis (FIB-4) tracked in the direction of histologic improvement. Adverse events were consistent with the known GLP-1 class profile — predominantly gastrointestinal — and consistent with the rates seen in STEP-1 (Wilding 2021, NEJM, the pivotal weight-management trial)[3] and SELECT (Lincoff 2023).[5]

Magnitude comparison

ESSENCE phase 3 trial results: histologic endpoints in MASH F2-F3 at week 72. Both co-primary endpoints met statistical significance and drove the Wegovy MASH supplemental FDA approval in August 2025. The placebo arms received the same lifestyle counseling background but no active drug.[1]

  • MASH resolution w/o fibrosis worsening — semaglutide 2.4 mg62.9 % of patients
    ESSENCE co-primary #1
  • MASH resolution w/o fibrosis worsening — placebo34.3 % of patients
    diet + lifestyle baseline
  • Fibrosis improvement ≥1 stage w/o MASH worsening — semaglutide36.8 % of patients
    ESSENCE co-primary #2
  • Fibrosis improvement ≥1 stage w/o MASH worsening — placebo22.4 % of patients
    diet + lifestyle baseline
ESSENCE phase 3 trial results: histologic endpoints in MASH F2-F3 at week 72. Both co-primary endpoints met statistical significance and drove the Wegovy MASH supplemental FDA approval in August 2025. The placebo arms received the same lifestyle counseling background but no active drug.

Cardiovascular + liver dual benefit (SELECT bonus)

The MASH approval is clinically meaningful on its own, but it is also strategically meaningful because Wegovy is the only drug in any class that now carries FDA-approved indications for both liver histologic improvement and cardiovascular event reduction. Patients with MASH F2-F3 fibrosis are at high cardiovascular risk independent of their liver disease — both conditions share the metabolic-syndrome substrate — and CV events are a leading cause of mortality in MASH patients, not liver-related events themselves until late-stage fibrosis or cirrhosis.

SELECT (Lincoff et al., NEJM 2023) randomized 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo, with a median follow-up of 39.8 months. The primary MACE composite (CV death, nonfatal MI, nonfatal stroke) occurred in 6.5% of the semaglutide group vs 8.0% of placebo (HR 0.80, 95% CI 0.72–0.90, p<0.001). SELECT supported the March 2024 FDA label expansion that added a cardiovascular indication to Wegovy.[5]

For the prescriber, this means a single weekly injection can now be prescribed on three coherent labeled indications in the same patient: an adult with obesity, biopsy-confirmed MASH F2-F3, and established cardiovascular disease meets every indication on the current Wegovy label simultaneously. That is an unusual situation in pharmacotherapy — most drugs carry one indication that prescribers use, with off-label leverage for the rest. For deeper coverage of the SELECT trial itself, see the SELECT trial cardiovascular benefits explainer.

Eligibility criteria for the Wegovy MASH indication

Per the updated DailyMed label, Wegovy is indicated for adults with all of the following:[9]

  • Confirmed MASH — either by liver biopsy (the gold standard used in ESSENCE) or by a non-invasive diagnostic pathway that hepatology specialists accept as sufficiently specific. Most insurers will require either a biopsy report or a documented diagnostic algorithm.
  • Moderate-to-advanced liver fibrosis — NASH-CRN stage F2 or F3. F2 indicates significant fibrosis with bridging beginning; F3 indicates advanced bridging fibrosis. F0-F1 (no or mild fibrosis) is below the indication threshold.
  • No cirrhosis — F4 cirrhosis is explicitly excluded. ESSENCE did not enroll cirrhotic patients, and the FDA approval reflects the trial population. Patients with decompensated cirrhosis or hepatocellular carcinoma history fall outside the indication entirely.
  • Adult patient — 18 years or older. The MASH indication has not been extended to adolescents, even though Wegovy carries a chronic-weight-management indication down to age 12. Pediatric MASH is an active research area but no GLP-1 carries a pediatric MASH approval as of 2026.
  • No standard contraindications to Wegovy — personal or family history of medullary thyroid carcinoma or MEN 2 syndrome; prior serious hypersensitivity to semaglutide; pregnancy (the label recommends discontinuation at least 2 months before a planned pregnancy due to the long half-life).

The non-invasive diagnostic pathway in clinical practice typically proceeds: primary-care screening with FIB-4 score for any patient with metabolic risk factors and elevated transaminases; hepatology referral for FIB-4 ≥1.3; transient elastography (FibroScan) for non-invasive fibrosis staging at the hepatology visit; and liver biopsy when the elastography result is indeterminate or when documenting biopsy-confirmed disease is needed for insurance prior authorization. Insurance plans are increasingly accepting FibroScan with kPa thresholds (typically ≥8.0 kPa as proxy for F2 and ≥9.7 kPa as proxy for F3) in lieu of biopsy, but policy varies by payer.

What about Zepbound? SYNERGY-NASH data

SYNERGY-NASH (Loomba et al., NEJM 2024) is the phase 2 trial of tirzepatide in MASH. It randomized adults with biopsy- confirmed MASH and fibrosis F2-F3 to tirzepatide 5 mg, 10 mg, or 15 mg weekly or placebo for 52 weeks, with paired liver biopsies at endpoint. Results were strongly positive across all three doses on the MASH-resolution endpoint:[2]

  • Tirzepatide 5 mg: 51.8% MASH resolution without worsening of fibrosis at week 52
  • Tirzepatide 10 mg: 62.8% MASH resolution
  • Tirzepatide 15 mg: 73.3% MASH resolution
  • Placebo: 13.2% MASH resolution

The 73.3% MASH resolution at the 15 mg dose is the highest rate seen in any GLP-1 trial in this population, including ESSENCE. However, SYNERGY-NASH was a phase 2 study with a 190-patient per-arm sample and a shorter follow-up than ESSENCE; it was not powered for the dual co-primary endpoint structure (MASH resolution AND fibrosis improvement) that the FDA requires for a MASH indication.

Status as of May 2026: Eli Lilly has initiated a phase 3 tirzepatide MASH program based on the SYNERGY-NASH signal. As of the publication of this article, tirzepatide is not FDA-approved for MASH. Prescriptions of Zepbound (the tirzepatide chronic-weight-management product) for the MASH indication would be off-label. Insurance coverage for Zepbound in MASH is accordingly limited, in contrast to Wegovy which has the on-label path.

For a fuller head-to-head between the two drug classes outside the MASH context — weight-loss magnitude, cost, side-effect profile — see the Wegovy alternatives in 2026 landscape piece.

Saxenda + Foundayo — no liver indication

Among the other FDA-approved GLP-1 receptor agonists, none has a MASH indication as of May 2026:

  • Saxenda (liraglutide 3.0 mg daily): FDA-approved for chronic weight management only. Smaller exploratory MASH studies of liraglutide (notably the LEAN trial) showed encouraging signals on histology, but no pivotal phase 3 MASH program was completed and Novo Nordisk did not pursue a MASH indication for the older liraglutide product. Saxenda prescriptions for MASH would be off-label.
  • Foundayo (orforglipron): The first oral non-peptide GLP-1 receptor agonist, FDA-approved in 2025 for chronic weight management. There is no published phase 3 MASH trial of orforglipron as of this article, and no FDA-approved MASH indication. A phase 2 MASH study has been announced.
  • Victoza (liraglutide 1.2-1.8 mg daily): FDA-approved for T2D glycemic control. No MASH indication.
  • Trulicity (dulaglutide): FDA-approved for T2D glycemic control and cardiovascular risk reduction in T2D patients. No MASH indication.
  • Mounjaro (tirzepatide for T2D): Same molecule as Zepbound but FDA-approved only for T2D. No MASH indication.
  • Ozempic (semaglutide for T2D): Same molecule as Wegovy but capped at the 2.0 mg weekly maximum. No MASH indication on the Ozempic label, even though the Wegovy label carries one for the same molecule at higher dose.

For a full reference table of every FDA-approved GLP-1 by indication, dose, and manufacturer, see the full GLP-1 medication list reference. For the broader landscape of trials reading out in 2026 — including SURMOUNT-MMO, the tirzepatide MASH phase 3, and the next CagriSema readouts — see the quarterly GLP-1 trial results tracker.

Lifestyle adjuncts per AASLD 2023 guidance

The AASLD 2023 practice guidance (Rinella et al., Hepatology) and its 2024 nomenclature-update companion (Kanwal et al., Hepatology) frame Wegovy as an adjunct to lifestyle intervention, not a replacement for it. Lifestyle remains foundational, and the histologic gains in ESSENCE were on top of a lifestyle-counseling background in both arms.[6][8]

The AASLD recommendations that intersect most directly with the Wegovy MASH treatment plan:

  • Body-weight reduction of at least 7-10% is associated with histologic improvement in MASH, with greater weight loss producing more consistent fibrosis improvement. Wegovy 2.4 mg typically produces -10 to -15% body-weight reduction at 68 weeks (STEP-1, ESSENCE), which puts most patients into the histologic-improvement zone independent of the drug’s direct hepatic effects.
  • Mediterranean dietary pattern is the preferred dietary approach for MASLD/MASH per AASLD — higher in monounsaturated fats (olive oil), vegetables, legumes, fish, and whole grains; lower in red meat, refined carbohydrate, and ultra-processed foods. The Mediterranean pattern is preferred over low-fat dietary patterns specifically for liver outcomes.
  • Aerobic exercise 150-200 minutes per weekplus resistance training, independent of weight loss, is recommended. Exercise improves hepatic insulin sensitivity and reduces intrahepatic triglyceride independent of weight change. On Wegovy, the appetite suppression often makes meeting protein and total caloric targets harder, and resistance training becomes particularly important for preserving lean mass.
  • Alcohol minimization or abstinence. For MASLD/MASH patients with fibrosis stage F2 or higher, AASLD recommends alcohol abstinence. For F0-F1 MASH, minimization is recommended. The patient population on the Wegovy MASH indication is F2-F3 by definition, which means abstinence is the standard recommendation alongside the medication.
  • Coffee consumption is associated with reduced liver-related outcomes in observational data and is not discouraged for MASLD/MASH patients (caffeinated or decaffeinated). This is not part of the MASH treatment plan per se, but it is in the practice-guidance document and patients ask about it.

For patients new to Wegovy, the first month carries the steepest learning curve on dosing, injection technique, and GI tolerance management — see the starting Wegovy first-month guide for the practical playbook.

Cost + insurance for the MASH indication

Coverage for Wegovy under the MASH indication is still evolving as of mid-2026 because the indication is new. The practical landscape:

  • Cash-pay through NovoCare Pharmacy: Novo Nordisk continues to list a $499/month self-pay price for Wegovy regardless of the prescribing indication. A MASH patient who cannot get insurance coverage can access the drug at the same cash price as a chronic-weight-management patient.
  • Retail list (WAC) without NovoCare: Roughly $1,349/month at full retail before any discount or insurance.
  • Commercial insurance for MASH: Most commercial plans have published medical policies covering Wegovy under the MASH indication when the prescriber documents biopsy- confirmed MASH (or accepted non-invasive surrogates) plus F2-F3 fibrosis. The clinical-documentation burden is higher than for the chronic-weight-management indication — a hepatology consult note, a FibroScan or biopsy report, and appropriate ICD-10 coding (K75.81 for steatohepatitis with fibrosis) are typically required.
  • Medicare Part D for MASH: This is the structurally important wrinkle. Medicare Part D is statutorily prohibited from covering drugs “for the treatment of anorexia, weight loss, or weight gain.” That statutory exclusion has historically blocked Wegovy under the chronic- weight-management indication. The cardiovascular indication (added 2024) routes around the exclusion because MACE reduction is treated as a separate medical-disease indication. The MASH indication routes around the exclusion on the same logic — MASH is a liver disease, not a weight-loss treatment — and Part D plans have begun adding Wegovy to formulary for MASH-indicated patients in 2026.
  • Prior authorization: Even in plans that cover Wegovy for MASH, expect a prior-authorization step requiring hepatology involvement and documentation of fibrosis staging. Step therapy through other MASH treatments is generally not required because no other treatments are FDA-approved — Wegovy is currently the sole on-label option.

For the broader cost landscape across compounded and brand GLP-1 options — relevant when Wegovy coverage falls through and a patient is weighing alternatives — see the cheapest GLP-1 without insurance buyer guide.

Bottom line

  • Wegovy is the first GLP-1 with an FDA-approved MASH indication. The August 2025 supplemental approval covers adults with non-cirrhotic MASH and moderate-to-advanced fibrosis (NASH-CRN stage F2 or F3), based on the ESSENCE phase 3 trial.
  • ESSENCE hit both co-primary histologic endpoints. 62.9% vs 34.3% for MASH resolution without fibrosis worsening, and 36.8% vs 22.4% for fibrosis improvement without MASH worsening, at week 72 on paired biopsy.
  • Wegovy is the only drug in any class with simultaneous FDA-approved indications for chronic weight management, cardiovascular event reduction, and MASH. A single weekly injection can be prescribed on-label for three coherent indications in the same patient.
  • Zepbound (tirzepatide) is not yet FDA-approved for MASH. SYNERGY-NASH phase 2 showed 73.3% MASH resolution at the 15 mg dose; a phase 3 program is underway, but as of May 2026 prescriptions for MASH would be off-label.
  • Saxenda, Foundayo, Victoza, Trulicity, Mounjaro, Ozempic — none carry a MASH indication. Only the Wegovy label.
  • Lifestyle remains foundational per AASLD. 7-10% body-weight reduction, Mediterranean dietary pattern, 150-200 minutes/week of aerobic exercise plus resistance training, alcohol abstinence at F2 or higher. Wegovy is an adjunct to those measures.
  • Insurance coverage for MASH routes around the Medicare statutory anti-obesity exclusion on the same logic as the 2024 cardiovascular indication. Coverage is still evolving; NovoCare Pharmacy direct-pay remains $499/month.

Frequently asked questions

References

  1. 1.Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). 1,197 adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 randomized to semaglutide 2.4 mg weekly vs placebo; week 72 paired liver biopsies. Co-primary endpoints: resolution of steatohepatitis without worsening of fibrosis (62.9% semaglutide vs 34.3% placebo) and improvement of fibrosis by at least one stage without worsening of MASH (36.8% vs 22.4%). Pivotal trial supporting the FDA Wegovy MASH supplemental approval in August 2025. N Engl J Med. 2025. PMID: 40305708.
  2. 2.Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). Phase 2 trial of tirzepatide 5 mg, 10 mg, or 15 mg weekly vs placebo in adults with biopsy-confirmed MASH and fibrosis F2-F3 over 52 weeks. MASH resolution without worsening of fibrosis: 51.8% (5 mg), 62.8% (10 mg), 73.3% (15 mg) vs 13.2% placebo. Tirzepatide is not yet FDA-approved for the MASH indication as of May 2026. N Engl J Med. 2024. PMID: 38856224.
  3. 3.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Semaglutide 2.4 mg once weekly produced mean body-weight reduction of -14.9% vs -2.4% placebo at 68 weeks. The pivotal trial that supported the FDA approval of Wegovy for chronic weight management. N Engl J Med. 2021. PMID: 33567185.
  4. 4.Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Pivotal T2D monotherapy trial for semaglutide 0.5 mg and 1.0 mg weekly (the Ozempic dose ladder). Lancet Diabetes Endocrinol. 2017. PMID: 28110911.
  5. 5.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). Semaglutide 2.4 mg once weekly produced a 20% relative reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72-0.90, p<0.001) in adults with established CV disease and overweight/obesity but without diabetes. Foundational cardiovascular evidence for the Wegovy label and the dual MASH + CV framing for the 2025 indication expansion. N Engl J Med. 2023. PMID: 37952131.
  6. 6.Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. The 2023 AASLD foundational guidance document — risk-stratification (FIB-4, elastography), Mediterranean dietary pattern, weight loss target ≥7-10% body weight, structured exercise ≥150-200 min/week, alcohol minimization (abstinence at ≥F2). Pre-MASLD-nomenclature publication superseded in language by Kanwal 2024 but still the underlying clinical guidance. Hepatology. 2023. PMID: 36727674.
  7. 7.Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, et al.; NAFLD Nomenclature Consensus Group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. The Delphi consensus that replaced NAFLD with MASLD and NASH with MASH; introduced the cardiometabolic-risk-factor criterion as the definitional anchor. Hepatology. 2023. PMID: 37363821.
  8. 8.Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance. The 2024 AASLD update mapping the prior NAFLD/NASH practice guidance onto the new MASLD/MASH nomenclature without changing clinical recommendations. Hepatology. 2024. PMID: 38445559.
  9. 9.Novo Nordisk Inc. WEGOVY (semaglutide) injection, for subcutaneous use — US Prescribing Information. SetID ee06186f-2aa3-4990-a760-757579d8f77b (version 18, effective 2026-05-05). §1 Indications and Usage: chronic weight management; cardiovascular risk reduction in adults with established CV disease and obesity or overweight; treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis. Boxed warning for thyroid C-cell tumors. FDA Approved Labeling (DailyMed NIH). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Glossary references

Key terms in this article, linked to their canonical definitions.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber or hepatologist. MASH is a serious progressive liver disease; diagnosis, fibrosis staging, and treatment selection should be performed by a qualified clinician with access to the full FDA prescribing information and the individual patient’s history. Wegovy carries an FDA boxed warning and multiple contraindications. Every regulatory claim in this article is anchored to a primary source (DailyMed or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.